Artivion, Inc. (NYSE:AORT - Get Free Report) SVP Jean F. Holloway sold 8,070 shares of the business's stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $30.12, for a total transaction of $243,068.40. Following the transaction, the senior vice president now directly owns 153,862 shares in the company, valued at approximately $4,634,323.44. The trade was a 4.98 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Artivion Trading Down 1.4 %
Shares of AORT stock opened at $29.50 on Friday. Artivion, Inc. has a fifty-two week low of $16.48 and a fifty-two week high of $30.45. The company has a 50 day moving average price of $27.65 and a 200 day moving average price of $26.16. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.33 and a current ratio of 1.88.
Hedge Funds Weigh In On Artivion
Several institutional investors have recently modified their holdings of the business. nVerses Capital LLC acquired a new position in shares of Artivion during the second quarter worth about $28,000. Quarry LP lifted its position in shares of Artivion by 210.8% during the 3rd quarter. Quarry LP now owns 1,209 shares of the company's stock worth $32,000 after purchasing an additional 820 shares during the last quarter. RiverPark Advisors LLC purchased a new position in Artivion in the second quarter valued at $55,000. RW Investment Management LLC purchased a new stake in Artivion during the 2nd quarter worth about $219,000. Finally, Intech Investment Management LLC acquired a new position in shares of Artivion during the 2nd quarter worth about $253,000. Institutional investors and hedge funds own 86.37% of the company's stock.
Wall Street Analyst Weigh In
Missed Nvidia? Buy Elon Musk’s “Silent Partner”
From Brownstone Research | Ad
In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my favorite stocks.
Today, it’s probably the most popular stock in the world.
I believe this Elon Musk “silent partner” could be the next big AI winner.
So please click here to see the details because a lot of people could get rich.
A number of analysts have recently issued reports on AORT shares. JMP Securities restated a "market outperform" rating and set a $33.00 price target on shares of Artivion in a report on Tuesday. Oppenheimer upped their target price on shares of Artivion from $30.00 to $32.00 and gave the company an "outperform" rating in a research report on Friday, November 8th. Needham & Company LLC restated a "buy" rating and set a $34.00 price target on shares of Artivion in a research note on Monday. Finally, Stifel Nicolaus raised their price target on Artivion from $28.00 to $30.00 and gave the stock a "buy" rating in a research report on Friday, September 13th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of "Buy" and a consensus target price of $31.80.
Get Our Latest Stock Report on AORT
Artivion Company Profile
(
Get Free Report)
Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
